I-Mab (IMAB)

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX) Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME Company core asset, givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, continues to advance under previously announced investment plans ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NovaBridge or the Company) today announced that it has changed its corporate name from I-Mab to NovaBridge Biosciences.

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, today announced that updated data from the Phase 1 study (NCT04900818) of givastomig as a monotherapy in heavily pre-treated patients (n=45) with gastroesophageal carcinoma (GEC) will be presented as a “short-talk” at the Triple Meeting on October 23, 2025 in Boston, Massachusetts (Presentation #B016). Givastomig is a bispecific antibody targeting CLDN18.2 (Claudin 18.2) and 4-1BB.

I-Mab (NASDAQ:IMAB ) Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDT Company Participants Xi-Yong Fu - CEO & Director Wei Fu - Executive Chairman Emmett T. Cunningham Kyler Lei Conference Call Participants PJ Kelleher Daina Graybosch - Leerink Partners LLC, Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division Presentation Operator Good day, and welcome to the I-Mab Business Update Call.

ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, announced its new business model, focused on its global capabilities built to accelerate access to innovative medicines and to enable broad strategic growth. The Company announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences.

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md. , Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U. S. -based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated patients with gastroesophageal carcinoma (GEC) has been accepted as a "short-talk" at the AACR-NCI-EORTC conference which will be held October 22-26 in Boston, Massachusetts.

Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

I-Mab has pivoted to focus on givastomig for gastric cancer, after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with promising ORR and safety, but key Phase 1b/2 data in Q1 2026 will be critical. Despite past setbacks, I-Mab's cash runway and undervalued market cap position it for potential upside if upcoming data is positive.

Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of May 28, 2025. The Company also announced Lielie Zhang will be stepping down from the Board, effective as of August 20, 2025, with gratitude for his dedicated service. In addition, I-Mab announced the formation of a Research and Development Committee of the Board of Directors (the R&D Committee), to be chaired by Dr. Robert Lenz, with Dr. Sean Cao and Dr. Sean Fu, Chief Executive Officer of I-Mab, as members. I-Mab will also expand its Scientific Advisory Board (SAB) with the appointment of Dr. Ken Takeshita.

ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the following upcoming investor conferences in September, 2025:

- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares (ADSs) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately $65 million. All of the ADSs to be sold in the offering will be offered by I-Mab. The offering is expected to close on August 5, 2025, subject to customary closing conditions.

ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd. (Bridge Health). The transaction provides I-Mab with the rights to bispecific and multi-specific applications (including bispecific and multi-specific antibodies and antibody drug conjugates (ADCs)), based on the Claudin 18.2 (CLDN18.2) parental antibody used in the Company's CLDN18.2 x 4-1BB bispecific antibody, givastomig.